Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Lineage Cell Therapeutics develops off-the-shelf allogeneic cell therapies targeting neurological and ophthalmic conditions. Its programs include retinal cell replacement for age-related macular degeneration and spinal cord injury repair using pluripotent stem cell-derived cells. The company leverages proprietary differentiation, manufacturing, and delivery technologies, collaborating with partners like Roche. Its focus is on regenerative treatments that restore or support damaged tissues, with a pipeline spanning clinical and preclinical stages.
This description was generated via AI from an annual report. Updated about 1 year ago.